Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912908 | 0.89 | KDM4E (0.42) | PDE10A | |
| SCHEMBL13912910 | 0.87 | KDM4E (0.41) | PDE10A | |
| SCHEMBL4311454 | 0.86 | PDE10A (0.36) | PDE10A | |
| SCHEMBL4308792 | 0.82 | PDE10A (0.36) | PDE10A | |
| SCHEMBL4316031 | 0.82 | PDE10A (0.37) | PDE10A | |
| SCHEMBL4311738 | 0.81 | PDE10A (0.35) | PDE10A | |
| SCHEMBL4312044 | 0.81 | PDE10A (0.34) | PDE10A | |
| SCHEMBL4310984 | 0.80 | PDE10A (0.36) | PDE10A | |
| SCHEMBL4305133 | 0.80 | PDE10A (0.36) | PDE10A | |
| SCHEMBL4307306 | 0.79 | CCR9 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40697-E1 | Method for making an aromatic polycarbonate | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2009-04-07 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-6790929-B2 | EXTRUSION GRAFTING AN OLIGOMERIZED POLYCARBONATE IN METHYL SALICYLATE SOLUTION, HEATING TO DESOLVENTIZE; A HIGH LEVEL OF ENDCAPPING, LOW LEVELS OF RESIDUAL SOLVENT | GENERAL ELECTRIC COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20030236384-A1 | METHOD FOR MAKING AN AROMATIC POLYCARBONATE | GENERAL ELECTRIC COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | PDE10A 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.